IgLON5 antibody disease is a rare autoimmune neurological disorder in which antibodies target the IgLON5 neuronal protein, causing sleep disturbances (severe sleep apnea and abnormal REM/NREM behaviors), movement and gait problems, bulbar dysfunction, cognitive decline, and autonomic symptoms. It combines immune-mediated injury with neurodegeneration and tau pathology. The disease is progressive; some patients respond variably to immunotherapy.

Igon 5 is not a recognized disease name in mainstream medical literature. It may be a product or brand label, a misprint, or a nonstandard term. If you encountered it on packaging, a report, or online, keep the item and consult a pharmacist or healthcare professional for clarification and safe next steps. Do not assume diagnosis or treatment without medical advice.

IgLON stands for immunoglobulin-like cell adhesion molecule. IgLONs are a family of GPI‑anchored neuronal cell adhesion proteins with immunoglobulin‑like domains (typically three) that mediate homophilic and heterophilic interactions, affecting neurite outgrowth, synapse formation, and neural circuit assembly. Members include LSAMP, NEGR1, OPCML, LAMP, and neurotrimin (NTM); they’re implicated in brain development and neuropsychiatric vulnerability.

IgLON5 disease is not considered hereditary. It’s an uncommon autoimmune neurological disorder linked to antibodies against the IgLON5 protein, and most cases are sporadic. Certain HLA genetic variants may increase susceptibility, but there is no clear pattern of familial inheritance or predictable transmission to relatives. Research continues to clarify genetic risk factors.

Prognosis for anti-IgLON5 disease is variable but often progressive and disabling. Many patients experience chronic neurological decline, sleep and bulbar dysfunction, and respiratory complications that can increase mortality. Early immunotherapy and symptomatic care may stabilize or improve symptoms in some cases, but responses are unpredictable and many individuals have persistent deficits and reduced long-term survival, especially with delayed treatment.

Autoimmune antibodies often persist and can fluctuate over time. In some situations—post-infection, drug-induced autoimmunity, or in children—antibodies may disappear, but in established autoimmune diseases they usually remain. Treatments (immunosuppression, biologics, plasmapheresis) can lower levels and improve symptoms, yet complete disappearance is uncommon. Discuss testing and treatment options with your clinician.